Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival

References

• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364:1046-60; PMID:21410373; http://dx.doi.org/10.1056/NEJMra1011442
   PubMed Web of Science ®Google Scholar
• Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7:585-98; PMID:17646864; http://dx.doi.org/10.1038/nrc2189
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, San-Miguel JF, Anderson KC. Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Eur J Haematol 2011; 86:1-15; PMID:20942854; http://dx.doi.org/10.1111/j.1600-0609.2010.01542.x
   PubMed Web of Science ®Google Scholar
• Borrello I. Can we change the disease biology of multiple myeloma? Leuk Res 2012; 36(Suppl 1):S3-12; PMID:23176722; http://dx.doi.org/10.1016/S0145-2126(12)70003-6
   PubMedGoogle Scholar
• Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8:479-91; PMID:21522124; http://dx.doi.org/10.1038/nrclinonc.2011.63
   PubMed Web of Science ®Google Scholar
• Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009; 23:10-24; PMID:18843284; http://dx.doi.org/10.1038/leu.2008.259
   PubMed Web of Science ®Google Scholar
• Noonan K, Borrello I. The immune microenvironment of myeloma. Cancer Microenviron 2011; 4:313-23; PMID:21866321; http://dx.doi.org/10.1007/s12307-011-0086-3
   PubMedGoogle Scholar
• Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245
   PubMed Web of Science ®Google Scholar
• Protti MP, Monte LD, Lullo GD. Tumor antigen-specific CD4(+) T cells in cancer immunity: from antigen identification to tumor prognosis and development of therapeutic strategies. Tissue Antigens 2014; 83:237-46; PMID:24641502; http://dx.doi.org/10.1111/tan.12329
   PubMedGoogle Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
   PubMed Web of Science ®Google Scholar
• De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 2011; 208:469-78; PMID:21339327; http://dx.doi.org/10.1084/jem.20101876
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci U S A 2002; 99:13009-13; PMID:12235374; http://dx.doi.org/10.1073/pnas.202491499
   PubMed Web of Science ®Google Scholar
• Noonan K, Matsui W, Serafini P, Carbley R, Tan G, Khalili J, Bonyhadi M, Levitsky H, Whartenby K, Borrello I. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res 2005; 65:2026-34; PMID:15753403; http://dx.doi.org/10.1158/0008-5472.CAN-04-3337
   PubMed Web of Science ®Google Scholar
• Dhodapkar KM, Barbuto S, Matthews P, Kukreja A, Mazumder A, Vesole D, Jagannath S, Dhodapkar MV. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 2008; 112:2878-85; PMID:18669891; http://dx.doi.org/10.1182/blood-2008-03-143222
   PubMed Web of Science ®Google Scholar
• Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman GD, Borrello I. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 2010; 116:3554-63; PMID:20664052; http://dx.doi.org/10.1182/blood-2010-05-283895
   PubMed Web of Science ®Google Scholar
• Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W, Pai C, Amin S, Tai YT, Richardson PG, et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010; 115:5385-92; PMID:20395418; http://dx.doi.org/10.1182/blood-2009-10-246660
   PubMed Web of Science ®Google Scholar
• Bryant C, Suen H, Brown R, Yang S, Favaloro J, Aklilu E, Gibson J, Ho PJ, Iland H, Fromm P, et al. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer J 2013; 3:e148; PMID:24036947; http://dx.doi.org/10.1038/bcj.2013.34
   PubMed Web of Science ®Google Scholar
• Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009; 10:857-63; PMID:19578369; http://dx.doi.org/10.1038/ni.1767
   PubMed Web of Science ®Google Scholar
• Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009; 10:864-71; PMID:19578368; http://dx.doi.org/10.1038/ni.1770
   PubMed Web of Science ®Google Scholar
• Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, Cianfarani F, Odorisio T, Traidl-Hoffmann C, Behrendt H, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009; 119:3573-85; PMID:19920355
   PubMed Web of Science ®Google Scholar
• Nograles KE, Zaba LC, Shemer A, Fuentes-Duculan J, Cardinale I, Kikuchi T, Ramon M, Bergman R, Krueger JG, Guttman-Yassky E. IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 2009; 123:1244-52.e2; PMID:19439349; http://dx.doi.org/10.1016/j.jaci.2009.03.041
   PubMedGoogle Scholar
• Sonnenberg GF, Fouser LA, Artis D. Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces. Adv Immunol 2010; 107:1-29; PMID:21034969; http://dx.doi.org/10.1016/B978-0-12-381300-8.00001-0
   PubMed Web of Science ®Google Scholar
• Ye ZJ, Zhou Q, Yin W, Yuan ML, Yang WB, Xiang F, Zhang JC, Xin JB, Xiong XZ, Shi HZ. Interleukin 22-producing CD4+ T cells in malignant pleural effusion. Cancer Lett 2012; 326:23-32; PMID:22809567; http://dx.doi.org/10.1016/j.canlet.2012.07.013
   PubMed Web of Science ®Google Scholar
• Xu X, Tang Y, Guo S, Zhang Y, Tian Y, Ni B, Wang H. Increased intratumoral interleukin 22 levels and frequencies of interleukin 22-producing CD4+ T cells correlate with pancreatic cancer progression. Pancreas 2014; 43:470-7; PMID:24622082; http://dx.doi.org/10.1097/MPA.0000000000000055
   PubMedGoogle Scholar
• Kryczek I, Lin Y, Nagarsheth N, Peng D, Zhao L, Zhao E, Vatan L, Szeliga W, Dou Y, Owens S, et al. IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity 2014; 40:772-84; PMID:24816405; http://dx.doi.org/10.1016/j.immuni.2014.03.010
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Peng LS, Zhao YL, Shi Y, Mao XH, Guo G, Chen W, Liu XF, Zhang JY, Liu T, et al. Increased intratumoral IL-22-producing CD4(+) T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival. Cancer Immunol Immunother 2012; 61:1965-75; PMID:22527243; http://dx.doi.org/10.1007/s00262-012-1241-5
   PubMed Web of Science ®Google Scholar
• Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, Bianchi G, Podar K, Tai YT, Mitsiades C, et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell 2009; 16:309-23; PMID:19800576; http://dx.doi.org/10.1016/j.ccr.2009.08.019
   PubMed Web of Science ®Google Scholar
• Feuerer M, Beckhove P, Garbi N, Mahnke Y, Limmer A, Hommel M, Hammerling GJ, Kyewski B, Hamann A, Umansky V, et al. Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med 2003; 9:1151-7; PMID:12910264; http://dx.doi.org/10.1038/nm914
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23:3412-20; PMID:15809451; http://dx.doi.org/10.1200/JCO.2005.04.242
   PubMed Web of Science ®Google Scholar
• Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. Defining the human T helper 17 cell phenotype. Trends Immunol 2012; 33:505-12; PMID:22682163; http://dx.doi.org/10.1016/j.it.2012.05.004
   PubMed Web of Science ®Google Scholar
• Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld JC. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 2002; 277:33676-82; PMID:12087100; http://dx.doi.org/10.1074/jbc.M204204200
   PubMed Web of Science ®Google Scholar
• Bard JD, Gelebart P, Anand M, Amin HM, Lai R. Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma. Leukemia 2008; 22:1595-603; PMID:18509351; http://dx.doi.org/10.1038/leu.2008.129
   PubMed Web of Science ®Google Scholar
• Gelebart P, Zak Z, Dien-Bard J, Anand M, Lai R. Interleukin 22 signaling promotes cell growth in mantle cell lymphoma. Transl Oncol 2011; 4:9-19; PMID:21286373; http://dx.doi.org/10.1593/tlo.10172
   PubMed Web of Science ®Google Scholar
• Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, et al. The molecular classification of multiple myeloma. Blood 2006; 108:2020-8; PMID:16728703; http://dx.doi.org/10.1182/blood-2005-11-013458
   PubMed Web of Science ®Google Scholar
• Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798-809; PMID:19851315; http://dx.doi.org/10.1038/nrc2734
   PubMed Web of Science ®Google Scholar
• Bochner BS, Klunk DA, Sterbinsky SA, Coffman RL, Schleimer RP. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol 1995; 154:799-803; PMID:7529288
   PubMed Web of Science ®Google Scholar
• Doucet C, Brouty-Boye D, Pottin-Clemenceau C, Jasmin C, Canonica GW, Azzarone B. IL-4 and IL-13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblasts. Int Immunol 1998; 10:1421-33; PMID:9796908; http://dx.doi.org/10.1093/intimm/10.10.1421
   PubMed Web of Science ®Google Scholar
• Sugita S, Kawazoe Y, Imai A, Kawaguchi T, Horie S, Keino H, Takahashi M, Mochizuki M. Role of IL-22- and TNF-alpha-producing Th22 cells in uveitis patients with Behcet's disease. J Immunol 2013; 190:5799-808; PMID:23630362; http://dx.doi.org/10.4049/jimmunol.1202677
   PubMed Web of Science ®Google Scholar
• Wolk K, Witte E, Witte K, Warszawska K, Sabat R. Biology of interleukin-22. Semin Immunopathol 2010; 32:17-31; PMID:20127093; http://dx.doi.org/10.1007/s00281-009-0188-x
   PubMed Web of Science ®Google Scholar
• Sonnenberg GF, Fouser LA, Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 2011; 12:383-90; PMID:21502992; http://dx.doi.org/10.1038/ni.2025
   PubMed Web of Science ®Google Scholar
• Lim C, Savan R. The role of the IL-22/IL-22R1 axis in cancer. Cytokine Growth Factor Rev 2014; 25:257-71; PMID:24856143; http://dx.doi.org/10.1016/j.cytogfr.2014.04.005
   PubMed Web of Science ®Google Scholar
• Ziesche E, Bachmann M, Kleinert H, Pfeilschifter J, Muhl H. The interleukin-22/STAT3 pathway potentiates expression of inducible nitric-oxide synthase in human colon carcinoma cells. J Biol Chem 2007; 282:16006-15; PMID:17438334; http://dx.doi.org/10.1074/jbc.M611040200
   PubMed Web of Science ®Google Scholar
• Zhang W, Chen Y, Wei H, Zheng C, Sun R, Zhang J, Tian Z. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res 2008; 14:6432-9; PMID:18927282; http://dx.doi.org/10.1158/1078-0432.CCR-07-4401
   PubMed Web of Science ®Google Scholar
• Jiang R, Tan Z, Deng L, Chen Y, Xia Y, Gao Y, Wang X, Sun B. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2011; 54:900-9; PMID:21674558; http://dx.doi.org/10.1002/hep.24486
   PubMed Web of Science ®Google Scholar
• Curd LM, Favors SE, Gregg RK. Pro-tumour activity of interleukin-22 in HPAFII human pancreatic cancer cells. Clin Exp Immunol 2012; 168:192-9; PMID:22471280; http://dx.doi.org/10.1111/j.1365-2249.2012.04570.x
   PubMedGoogle Scholar
• Tsirakis G, Pappa CA, Kolovou A, Kokonozaki M, Neonakis I, Alexandrakis MG. Clinical significance of interleukin-22 in multiple myeloma. Hematology 2015; 20:143-7; PMID:25055724; http://dx.doi.org/10.1179/1607845414Y.0000000182
   PubMedGoogle Scholar
• Mahindra A, Hideshima T, Anderson KC. Multiple myeloma: biology of the disease. Blood Rev 2010; 24(Suppl 1):S5-11; PMID:21126636; http://dx.doi.org/10.1016/S0268-960X(10)70003-5
   PubMedGoogle Scholar
• Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity 2004; 21:241-54; PMID:15308104; http://dx.doi.org/10.1016/j.immuni.2004.07.007
   PubMed Web of Science ®Google Scholar
• Anderson KC, Jones RM, Morimoto C, Leavitt P, Barut BA. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 1989; 73:1915-24; PMID:2713508
   PubMed Web of Science ®Google Scholar
• Klein B, Bataille R. Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am 1992; 6:273-84; PMID:1582974
   PubMed Web of Science ®Google Scholar
• Chng WJ, Fonseca R. Risk stratification of patients with newly diagnosed multiple myeloma: optimizing treatment based on pretreatment characteristics. Clin Lymphoma Myeloma 2005; 6:200-7; PMID:16354325; http://dx.doi.org/10.3816/CLM.2005.n.047
   PubMedGoogle Scholar
• Kyrtsonis MC, Maltezas D, Tzenou T, Koulieris E, Bradwell AR. Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma. Semin Hematol 2009; 46:110-7; PMID:19389494; http://dx.doi.org/10.1053/j.seminhematol.2009.02.004
   PubMedGoogle Scholar
• Avet-Loiseau H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J, Goldschmidt H, Hajek R, Lee JH, Sezer O, et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia 2013; 27:711-7; PMID:23032723; http://dx.doi.org/10.1038/leu.2012.282
   PubMed Web of Science ®Google Scholar
• Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, Montagna D, Maccario R, Villa R, Daidone MG, et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 2007; 67:9142-9; PMID:17909019; http://dx.doi.org/10.1158/0008-5472.CAN-06-4690
   PubMed Web of Science ®Google Scholar
• Pruneri G, Ponzoni M, Ferreri AJ, Freschi M, Tresoldi M, Baldini L, Mattioli M, Agnelli L, Govi S, Mancuso P, et al. The prevalence and clinical implications of c-kit expression in plasma cell myeloma. Histopathology 2006; 48:529-35; PMID:16623778; http://dx.doi.org/10.1111/j.1365-2559.2006.02375.x
   PubMed Web of Science ®Google Scholar